[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy].
OBJECTIVE
This study was undertaken to further determine the clinical value of ondansetron (OND, supplied by Qilu Pharmaceutical Company) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy.


METHODS
A total of 193 patients were enrolled in the multicenter prospective study and were given treatment of non-cisplatin based chemotherapy. All patients were treated with OND 8 mg i.v. once a day during chemotherapy, followed by OND 4 mg orally twice a day for one day after chemotherapy.


RESULTS
The effective control rate (0-2 emetic episodes) on the first day was 93.3%. Total control of delayed vomiting (day 2-5) was as high as 94.8 to 99.5%. The mean frequency of vomiting was 0.4, 0.4, 0.2, 0.1 and 0.1, respectively from day 1 to day 5. Adverse effects were minor and tolerable.


CONCLUSIONS
This modified regimen of treatment with OND is effective in the control of vomiting induced by non-DDP chemotherapy.
Zhou
J
J
Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing.
Xu
B
B
Zhou
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D017294:Ondansetron / Q000627:therapeutic use*; D011446:Prospective Studies; D014840:Vomiting, Anticipatory / Q000517:prevention & control*
D000932:Antiemetics; D017294:Ondansetron